Biogen Inc. (BIIB) Fundamentals

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
SHARE INFORMATION
Market Cap$ 31,393,756,588
Shares Outstanding145,113,047
Float128,425,300
Percent Float88.5%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per Share$ 0.00
Latest Fiscal Revenue$ 10,981,700,000
Latest Fiscal EPS$ 10.40
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)$ 0.00
Dividend (5 Years)$ 0.00
Ex Dividend Date-
Dividend Rate$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions2,128
Institutional Holdings Date2022-07-31
Institutional Bought Previous 3 Months10,166,284
Institutional Holdings Percent157.6%
Institutional Sold Previous 3 Months19,995,420
Insider Holdings Date2022-07-31
Insider Bought Previous 3 Months16,711
Insider Holdings Percent1.4
Insider Sold Previous 3 Months978
Insider Shares Owned2,088,181
TRADING INFO
52 Week High$ 351.86
52 Week Low$ 187.16
52 Week High Change$ -36.72
21 Day Moving Average$ 215.2267
21 Day Extended Moving Average$ 216.2627
50 Day Moving Average$ 211.2044
50 Day Extended Moving Average$ 212.7593
200 Day Moving Average$ 219.3144
200 Day Extended Moving Average$ 225.3084
10 Day Average Volume679,316
20 Day Average Volume799,090
30 Day Average Volume858,959
50 Day Average Volume990,524
Alpha-0.004248
Beta0.3953
Standard Deviation0.096923
R20.041604
7 Day Price Change$ -1.88
7 Day Percent Change-0.86%
21 Day Price Change$ 2.14
21 Day Percent Change1.0%
30 Day Price Change$ 2.00
30 Day Percent Change0.93%
Month to Date Price Change$ 1.28
Month to Date Percent Change0.6%
Quarter to Date Price Change$ 12.40
Quarter to Date Percent Change6.08%
180 Day Price Change$ 6.55
180 Day Percent Change3.12%
200 Day Price Change$ -8.87
200 Day Percent Change-3.94%
Year to Date Price Change$ -23.58
Year to Date Percent Change-9.83%

Biogen Inc. (BIIB) Key Ratios

PROFITABILITY
EBIT Margin24.2%
EBITDA Margin29.4%
Pre-Tax Profit Margin37.5%
Profit Margin Count15.39%
Gross Margin76.3%
Profit Margin TOT15.39%
INCOME STATEMENTS
Revenue$ 10,633,600,000
Revenue Per Share$ 73.278
Revenue (3 Years)$ 0.00
Revenue (5 Years)$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book7.80
Total Debt To Equity0.60
Int Coverage9.80
Current Ratio1.90
Leverage Ratio2.20
Quick Ratio1.40
Long Term Debt To Capital0.36
VALUATION MEASURES
PE Ratio15.50
Enterprise Value$ 34,327,196,766
Price to Sales2.9523
Price to Free Cash9.60
PE High Last 5 Years32.60
Price To Book2.70
Price To Cash Flow12.60
PE Low Last 5 Years7.10
Price to Tangible Book7.80
MANAGEMENT EFFECTIVENESS
Receivables Turnover5.10
Invoice Turnover1.80
Assets Turnover0.40
Return Assets8.82
Return on Equity19.27
Return on Capital11.45

Biogen Inc. (BIIB) Profile

PROFILE INFO
Issue TypeCS
SEC TypeEQS
AuditorPricewaterhouseCoopers LLP
CEOMichel Vounatsos
Emplyoees9610
Last AuditUQ
CIK0000875045
IndustryDrug Manufacturers
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address225 Binney Street
Cambridge, MA 2142
Websitehttp://www.biogen.com
Facsimile+1 302 636-5454
Telephone+1 617 679-2000
EmailIR@biogen.com


Your Recent History
NASDAQ
BIIB
Biogen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.